Staphyloccous aureus and coagulase negative staphylocci are responsible of a large marjority of PJI. Regarding the high rate of methicillin resistance, current guidelines recommend the use of a glycopeptide, and most frequently vancomycin, as the anti-gram positive agent in empirical therapy, while awaiting the microbiological results. Vancomycin is not considered as a safe antibiotic, and daptomycin is frequently an alternative option. Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. As some data report a synergistic activity with daptomycin, they could be an option in pandrug-resistant staphylococci BJI, but their use if off label in this indication.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Evaluation of use of ceftaroline and ceftobiprole : patients
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
Evaluation of use of ceftaroline: dosage
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
Evaluation of use of ceftaroline : PJI/BJI
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
Evaluation of use of ceftobiprole: dosage
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
Evaluation of use of ceftobiprole: PJI/BJI
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
rate of failure under ceftaroline
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
rate of failure under ceftobiprole
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)